MMCM
ABBV icon

Murphy & Mullick Capital Management’s AbbVie ABBV Stock Holding History

Murphy & Mullick Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$114K Buy
523
+1
+0.2% +$222 0.08% 183
2025
Q4 		$119K Buy
522
+2
+0.4% +$456 0.09% 187
2025
Q3 		$120K Buy
520
+1
+0.2% +$204 0.09% 181
2025
Q2 		$97.8K Hold
519
– – 0.08% 191
2025
Q1 		$109K Sell
519
-19
-4% -$3.69K 0.11% 170
2024
Q4 		$95.6K Buy
+538
New +$98.9K 0.09% 176

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Murphy & Mullick Capital Management's ABBV Position: Q1 2026 in Review

Murphy & Mullick Capital Management increased its AbbVie (ABBV) stake by 0.19% in Q1 2026, buying an estimated $222 and bringing the position to 523 shares worth $114K. The position accounts for 0.08% of the portfolio, ranked #183.

Murphy & Mullick Capital Management first reported a position in ABBV in Q4 2024 and has held it in 6 quarters since. The position peaked at $120K in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Murphy & Mullick Capital Management held 523 shares of AbbVie worth $114K as of Q1 2026.
  • Murphy & Mullick Capital Management bought 1 AbbVie share in Q1 2026, an estimated $222.
  • AbbVie made up 0.08% of Murphy & Mullick Capital Management's portfolio in Q1 2026, its #183 holding.
  • Murphy & Mullick Capital Management first reported a position in AbbVie in Q4 2024 and has held it in 6 quarters since.
  • Murphy & Mullick Capital Management's AbbVie position peaked at $120K in Q3 2025.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q1 2026, filed 17 Apr 2026.